361 related articles for article (PubMed ID: 19335045)
1. The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Gómez Portilla A; Cendoya I; Olabarría I; Martínez de Lecea C; Gómez Martínez de Lecea C; Gil A; Martín E; Muriel J; Magrach L; Romero E; Lirola A; Guede N; Moraza N; Fernández E; Kvadatze M; Valdovinos M; Larrabide I; Ruiz de Alegría N; Fernández JL; Castillo C; Rua O; Ulibarrena MA
Rev Esp Enferm Dig; 2009 Feb; 101(2):97-102, 103-6. PubMed ID: 19335045
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I
Trials; 2010 May; 11():62. PubMed ID: 20500867
[TBL] [Abstract][Full Text] [Related]
3. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
4. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
5. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis.
Passot G; You B; Boschetti G; Fontaine J; Isaac S; Decullier E; Maurice C; Vaudoyer D; Gilly FN; Cotte E; Glehen O
Ann Surg Oncol; 2014 Aug; 21(8):2608-14. PubMed ID: 24668148
[TBL] [Abstract][Full Text] [Related]
6. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal carcinomatosis of colorectal origin.
Elias D; Raynard B; Farkhondeh F; Goéré D; Rouquie D; Ciuchendea R; Pocard M; Ducreux M
Gastroenterol Clin Biol; 2006 Oct; 30(10):1200-4. PubMed ID: 17075479
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Pelz JO; Chua TC; Esquivel J; Stojadinovic A; Doerfer J; Morris DL; Maeder U; Germer CT; Kerscher AG
BMC Cancer; 2010 Dec; 10():689. PubMed ID: 21176206
[TBL] [Abstract][Full Text] [Related]
10. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
de Boer NL; Brandt-Kerkhof ARM; Madsen EVE; Diepeveen M; van Meerten E; van Eerden RAG; de Man FM; Bouamar R; Koolen SLW; de Hingh IHJT; Bakkers C; Rovers KP; Creemers GM; Deenen MJ; Kranenburg OW; Constantinides A; Mathijssen RHJ; Verhoef C; Burger JWA; ;
BMJ Open; 2019 Dec; 9(12):e034508. PubMed ID: 31818845
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update.
Gómez Portilla A; Cendoya I; López de Tejada I; Olabarría I; Martínez de Lecea C; Magrach L; Gil A; Echevarría J; Valdovinos M; Larrabide I
Rev Esp Enferm Dig; 2005 Oct; 97(10):716-37. PubMed ID: 16351464
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
13. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.
Elias D; Matsuhisa T; Sideris L; Liberale G; Drouard-Troalen L; Raynard B; Pocard M; Puizillou JM; Billard V; Bourget P; Ducreux M
Ann Oncol; 2004 Oct; 15(10):1558-65. PubMed ID: 15367418
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
[TBL] [Abstract][Full Text] [Related]
15. [Specific treatment situations in metastatic colorectal cancer].
Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
[TBL] [Abstract][Full Text] [Related]
16. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
Elias D; Pocard M; Goere D
Cancer Treat Res; 2007; 134():303-18. PubMed ID: 17633062
[No Abstract] [Full Text] [Related]
17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.
Rouers A; Laurent S; Detroz B; Meurisse M
Acta Chir Belg; 2006; 106(3):302-6. PubMed ID: 16910003
[TBL] [Abstract][Full Text] [Related]
18. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Sideris L; Mitchell A; Drolet P; Leblanc G; Leclerc YE; Dubé P
Can J Surg; 2009 Apr; 52(2):135-41. PubMed ID: 19399209
[TBL] [Abstract][Full Text] [Related]
19. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Elias D; Goere D; Blot F; Billard V; Pocard M; Kohneh-Shahri N; Raynard B
Ann Surg Oncol; 2007 Jun; 14(6):1818-24. PubMed ID: 17356950
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival.
Yan TD; Chu F; Links M; Kam PC; Glenn D; Morris DL
Eur J Surg Oncol; 2006 Dec; 32(10):1119-24. PubMed ID: 16887321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
